Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2009

Study Completion Date

January 31, 2010

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CEP-701

DRUG

high-dose cytarabine

Chemotherapy

DRUG

Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)

Chemotherapy

Trial Locations (81)

1023

Call For Information, Auckland

2065

Call For Information, Sydney

3004

Call For Information, Melbourne

3065

Call For Information, Fitzroy

4029

Call for Information, Herston

4101

Call For Information, South Brisbane

5000

Call For Information, Adelaide

6000

Call For Information, Perth

10021

New York Presbyterian, New York

10043

Call For Information, Turin

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh, Pittsburgh

15276

Call For Information, Bialystok

18009

Call For Information, Cherkassy

19104

University of Pennsylvania, Philadelphia

20022

Call For Information, Lublin

21201

Univeristy of Maryland Medicine - Greenebaum Cancer Center, Baltimore

21231

Johns Hopkins, Baltimore

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

30322

Emory University School of Medicine, Atlanta

31096

Call For Information, Haifa

31201

ACORN-Central Georgia Hematology/Oncology, Macon

31501

Call For Information, Krakow

33606

Moffitt Cancer Center, Tampa

35294

University of Alabama, Birmingham

38120

ACORN-The West Clinic, Memphis

40032

Call For Information, Katowice

41038

Call For Information, Bologna

44195

The Cleveland Clinic Foundation, Cleveland

46009

Call For Information, Valencia

46107

St. Francis Cancer Care Services, Beech Grove

46202

Indiana Cancer Pavillion, Indianapolis

48109

University of Michigan, Ann Arbor

48129

Call For Information, Münster

48201

Karmanos Cancer Institute Wayne State University, Detroit

49100

Call For Information, Petah Tikva

50369

Call For Information, Wroclaw

52242

University of Iowa Hospitals and Clinics, Iowa City

52621

Call For Information, Tel Litwinsky

55455

University of Minnesota, Minneapolis

55905

The Mayo Clinic, Rochester

60569

Call For Information, Poznan

60590

Call For Information, Frankfurt

60611

Northwestern University, Chicago

60637

University of Chicago, Chicago

63110

Washington University, St Louis

68198

University of Nebraska, Omaha

69120

Call For Information, Heidelberg

70376

Call For Information, Stuttgart

71103

LSU Shreveport, Shreveport

72205

University of Arkansas for Medical Sciences, Little Rock

77030

MD Anderson Cancer Center, Houston

79044

Call For Information, Lviv

80952

Call For Information, Gdansk

85259

Mayo-Scottsdale, Scottsdale

90033

USC/Norris Cancer Center, Los Angeles

93510

Call For Information, Lodz

94305

Stanford Medical Center, Stanford

98195

University of Washington Medical Center, Seattle

125167

Call For Information, Moscow

197022

Call For Information, Saint Petersburg

197110

Call For Information, Saint Petersburg

630099

Call For Information, Novosibirsk

700111

Call For Information, Iași

02111

Tufts New England Medical Center, Boston

02215

Beth Israel Hospital, Boston

M5G2M9

Princess Margaret Hospital, Toronto

G1J1Z4

CHA Hospital Enfant-Jesus, Québec

09113

Call For Information, Chemnitz

01307

Call For Information, Dresden

00133

Call For Information, Roma

00161

Call For Information, Roma

02097

Call For Information, Warsaw

02776

Call For Information, Warsaw

030171

Call For Information, Bucharest

08041

Call For Information, Barcelona

SE-22185

Call For Information, Lund

SE-17176

Call For Information, Stockholm

03115

Call For Information, Kiev

04112

Call For Information, Kiev

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00079482 - Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter